Constitutive expression of cellular retinoic acid binding protein II and lack of correlation with sensitivity to all-trans retinoic acid in acute promyelocytic leukemia cells

Cancer Research

Volumn 58, Issue 24, 1998, Pages 5770-5776

  Zhou, Da Cheng ^a   Hallam, Steven J ^a   Lee, Sandra J ^b   Klein, Robert S ^a   Wiernik, Peter H ^a   Tallman, Martin S ^c,d   Gallagher, Robert E ^a  

^a ALBERT EINSTEIN CANCER CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d Eastern Cooperative Oncology Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; DAUNORUBICIN; MESSENGER RNA; RETINOIC ACID; RETINOIC ACID BINDING PROTEIN;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESISTANCE; DRUG SENSITIVITY; FAST PROTEIN LIQUID CHROMATOGRAPHY; FEMALE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA REMISSION; MALE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CELL DIFFERENTIATION; DRUG RESISTANCE, NEOPLASM; HL-60 CELLS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; RECEPTORS, RETINOIC ACID; REMISSION INDUCTION; RNA, MESSENGER; TRETINOIN;

EID: 0032534955     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Breitman, T. R., Collins, S. J., and Keene, B. R. Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid. Blood, 57: 1000-1004, 1981.
2. Chomienne, C., Ballerini, P., Balitrand, N., Daniel, M. T., Fenaux, P., Castaigne, S., and Degos, L. All-trans retinoic acid in acute promyelocytic leukemias. II. In vitro studies: structure-function relationship. Blood, 76: 1710-1717, 1990.
3. Ellioit, S., Taylor, K., White, S., Rodwell, R., Marlton, P., Meagher, D., Wiley, J., Taylor, D., Wright, S., and Timms, P. Proof of differentiative mode of action of all-trans retinoic acid in acute promyelocytic leukemia using X-linked clonal analysis. Blood, 79: 1916-1919, 1992.
4. Huang, M-E., Ye, Y-C., Chen, S-R., Chai, J-R., Lu, J-X., Lin, Z., Gu, L-J., and Wang, Z-Y. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood, 72: 567-572, 1988.
5. Castaigne, S., Chomienne, C., Daniel, M. T., Ballerini, P., Berger, R., Fenaux, P., and Degos, L. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood, 76: 1704-1709, 1990.
6. Chen, Z-X., Xue, Y-Q., Zhang, R., Tao, R-F., Xia, X-M., Li, C., Wang, W., Zu, W-Y., Yao, X-Z., and Ling, B-J. A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood, 78: 1413-1419, 1991.
7. Frankel, S. R., Eardley, A., Heller, G., Berman, E., Miller, W. H., Jr., Dmitrovsky, E., and Warrell, R. P., Jr. All-trans-retinoic acid for acute promyelocytic leukemia: results of the New York study. Ann. Int. Med., 120: 278-286, 1994.
8. Tallman, M. S., Andersen, J. W., Schiffer, C. A., Appelbaum, F. R., Feusner, J. E., Ogden, A., Shepherd, L., Willman, C. L., Bloomfield, C. D., Rowe, J. M., and Wiernik, P. H. All-trans retinoic acid in acute promyelocytic leukemia. N. Engl. J. Med., 337: 1021-1028, 1997.
9. Miller, W., Jr., Jakubowski, A., Tong, W., Miller, V., Rigas, J., Benedetti, F., Gill, G., Truglia, J., Ulm, E., Shirley, M., and Warrell, R., Jr. 9-cis Retinoic acid induces complete remission but does not reverse clinically acquired retinoid resistance in acute promyelocytic leukema. Blood, 85: 3021-3027, 1995.
10. Warrell, R., Jr. Retinoid resistance in acute promyelocytic leukemia: new mechanisms, strategies and implications. Blood, 82: 1949-1953, 1993.
11. Adamson, P., Boylan, J., Balis, F., Murphy, R., Godwin, K., Gudas, L., and Poplack, D. Time course of induction of metabolism of all-trans-retinoic acid and the upregulation of cellular retinoic acid-binding protein. Cancer Res., 53: 472-476, 1993.
12. Muindi, J., Frankel, S., Huselton, C., DeGrazia, F., Garland, W., Young, C., and Warrell, R. P., Jr. Clinical pharmacology of oral all-trans retinoic acid with acute promyelocytic leukemia. Cancer Res., 52: 2138-2142, 1992.
13. Muindi, J., and Young, C. Lipid hydroperoxides greatly increase the rate of oxidative catabolism of all-trans-retinoic acid by human microsomes genetically enriched in specified cytochrome P-450 isoforms. Cancer Res., 53: 1226-1229, 1993.
14. Delva, L., Cornic, M., Balitrand, N., Guidez, F., Miclea, J-M., Delmer, A., Teillet, F., Fenaux, P., Castaigne, S., Degos, L., and Chomienne, C. Resistance to all-trans-retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: study of in vitro sensitivity and cellular retinoic acid binding protein levels in leukemic cells. Blood, 82: 2175-2181, 1993.
15. Ding, W., Li, Y. P., Nobile, L. M., Grills, G., Carrera, I., Paietta, E., Tallman, M. S., Wiernik, P. H., and Gallagher, R. E. Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARα fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy. Blood. 92: 1172-1183, 1998.
16. Robertson, K., Emami, B., and Collins, S. Retinoic acid-resistant HL-60R cells harbor a point mutation in the retinoic acid receptor ligand-binding domain that confers dominant negative activity. Blood, 80: 1885-1888, 1992.
17. Li, Y-P., Said, F., and Gallagher, R. Retinoic acid-resistant HL-60 cells exclusively contain mutant retinoic acid receptor-α. Blood, 83: 3298-3302, 1994.
18. Shao, W., Benedetti, L., Lamph, W. W., Nervi, C., and Miller, W. H., Jr. A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RARα mutation. Blood, 89: 4282-4289, 1997.